Management Team

Image
Olivier Taelman
Olivier Taelman
CEO

Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019.  Olivier spent 7 years in commercial healthcare at Eli Lilly and Sanofi Aventis leading specific Business Units. He spent 15 years within the field of neuromodulation at Medtronic, managing EMEA at Stryker NeuroVascular and serving a neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO.

Image
Loïc Moreau
Loïc Moreau
CFO

Loïc Moreau has served as our Chief Financial Officer since January 2022. He is a seasoned leader with more than 20 years of experience in Finance having held senior roles at GSK notably in M&A/Corporate Development or Country-CFO across different geographies. Prior to this, he started his career at EY (External Audit) and PwC (Corporate Finance). Loic holds a master from ESSCA Management School (France) and Master in Finance from Solvay University (Belgium).

Image
Bruno Onkelinx
Bruno Onkelinx
CTO

Bruno Onkelinx has 25 years of experience in highly regulated industries with the last 15 years in active implantable medical devices at Cochlear. At Cochlear he built successful teams while managing international research & development and manufacturing operations across Europe-Belgium and the US-Colorado. He led several core Cochlear products from ideation through development to commercial approval and manufacturing. During his last years at Cochlear, Bruno was leading global incubation activities supporting business development activities and external medical device start/scale-ups.

Image
An Moonen
An Moonen
General Counsel

An Moonen joined Nyxoah in December 2020 as General Counsel, bringing over 20 years of experience. After 11 years at Linklaters (Corporate M&A), she joined cell therapy company TiGenix in 2011 where she oversaw all legal and compliance matters as General Counsel and Company Secretary. An was involved in various strategic licensing, financing and M&A transactions, including TiGenix’ Nasdaq IPO and its takeover by Takeda. An holds a law degree from the KU Leuven and a Master of Laws (LLM) degree from New York University School of Law. She is a member of the New York Bar.

Image
Jeremy Feffer
Jeremy Feffer
VP Investor Relations and Corporate Communication

Jeremy Feffer brings to Nyxoah 20 years of experience in healthcare capital markets as a sell-side equity research analyst and an investor relations advisor. Jeremy covered medical device, diagnostics, and healthcare services companies as an analyst at Bank of America, Oppenheimer, and Cantor Fitzgerald. As an IR Director at LifeSci Advisors, he developed and executed comprehensive capital markets, corporate access, and messaging strategies for pre-IPO and publicly-traded healthcare companies. Jeremy holds an MBA from the Stern School of Business at New York University, a Diploma in Economics from the London School of Economics.

Image
Nathalie Gilat
Nathalie Gilat
VP Quality & Regulatory / General Manager Israel

Nathalie Gilat has over 14 years of experience in global clinical & regulatory affairs. When joining Nyxoah in 2014, Nathalie played a key role in its initial clinical studies obtaining CE mark and regulatory milestones in the US. Currently, Nathalie is leading the Israeli organization as General Manager. Prior to Nyxoah, Nathalie held various managerial roles in innovative medical device companies, such as Valtech Cardio (acquired by Edwards Lifesciences) and Ovalum vascular. Nathalie holds a Biomedical Engineering degree from Ben-Gurion University and an MBA from Tel Aviv University.

Image
Jeyakumar Subbaroyan
Jeyakumar Subbaroyan
VP Clinical Affairs

Jeyakumar Subbaroyan has 14 years of experience in clinical and pre-clinical neuromodulation research in the fields of urology, migraine, spinal cord injury, and various chronic pain conditions. He has successfully executed multiple clinical studies across the US, Europe and Australia managing diverse global teams. He has 4 issued patents and over 20 peer-reviewed publications. Prior to Nyxoah, Jey held various positions of increasing responsibility in medical device companies including Johnson & Johnson, Spinal Modulation Inc. (acquired by St. Jude Medical), Nevro Corp. and Onward Medical Inc. to name a few.

Image
Dorit Nahari
Dorit Nahari
VP Operations

Dorit has 13 years of experience in process manufacturing and quality management in highly regulated industries. She has successfully led both small and large groups in numerous manufacturing aspects including routine production, implementation of process changes, qualifications of new manufacturing sites and preparation to regulatory audits. She has extensive experience working in GMP and QSR/ISO 13485 regulated environments, including successful FDA, and EMA audits.

Dorit holds a MSc. in Food Engineering and Biotechnology from the Technion, Israel, a PhD in Integrative Biology from University of Texas Southwestern (UTSW) Medical Center Dallas, Texas, and an MBA from College of Management, Israel.

Image
Rémi Renard
Rémi Renard
VP Market Development & Education

Rémi Renard has 15 years of experience in Sales and Marketing.  Throughout his career he has held multiple sales and marketing positions in medical device firms, mostly in the Cardiac Rhythm Management and OSA fields at Resmed, Boston Scientific and St. Jude Medical. Notably he successfully led sales and marketing activities related to the introduction in international markets of the first to market leadless pacemaker.

Image
Patrick Tompkins
Patrick Tompkins
VP US Operations

Patrick Tompkins has over 20 years of executive leadership experience in the medical device space. He joined Nyxoah in 2020 as VP of US Operations with responsibility for managing Nyxoah’s US operations in their IDE trial. Patrick has previous commercial leadership experience, both with global and domestic responsibilities in the cardiac and neuro fields. The last 13 years with neuromodulation companies, 8 of which were with St Jude Medical. Patrick has introduced and led the commercialization efforts, of first to market innovative technologies in both the cardiac and the neuromodulation spaces.